6 patents currently held
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2030. from the record
Of the 9 now held by other companies, 9 name Hikma Pharmaceuticals USA Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
May 2030
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2030 · High confidence
Also notable
Ends Nov 2032 · High confidence
Also notable
Ends Nov 2031 · High confidence
Vaccines Against Herpes Simplex Virus Type 2: Compositions and Methods for Eliciting an Immune Response
US 8,617,564
The most cited patent in this portfolio, cited by 32 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2030.
Nucleic Acid Vaccines Against Herpes Simplex Virus Type 2: Compositions and Methods for Eliciting an Immune Response
US 9,624,273
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2032.
Vaccines Against Herpes Simplex Virus Type 2: Compositions and Methods for Eliciting an Immune Response
US 9,782,474
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2031.
Formerly held, still cited
Notable
Ends May 2028 · High confidence
The most cited patent in this portfolio, cited by 173 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028.
now held by Hikma Pharmaceuticals USA Inc.
Also notable
Ends Jan 2033 · Medium confidence
Cited by 68 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033.
now held by Hikma Pharmaceuticals USA Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Methods and Compositions for Treating Herpes (US 10,350,288) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 3 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,895,436 | Vaccines Against Herpes Simplex Virus Type 2: Compositions and Methods for Eliciting an Immune Response In force · High confidence | In force | High confidence | |
| US 10,653,771 | Vaccines Against Herpes Simplex Virus Type 2: Compositions and Methods for Eliciting an Immune Response In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 8,617,564 | Vaccines Against Herpes Simplex Virus Type 2: Compositions and Methods for Eliciting an Immune Response In force · High confidence | In force | High confidence | |
| US 9,782,474 | Vaccines Against Herpes Simplex Virus Type 2: Compositions and Methods for Eliciting an Immune Response In force · High confidence | In force | High confidence | |
| US 9,624,273 | Nucleic Acid Vaccines Against Herpes Simplex Virus Type 2: Compositions and Methods for Eliciting an Immune Response In force · High confidence | In force | High confidence | |
| US 10,350,288 | Methods and Compositions for Treating Herpes In force (reinstated) · High confidence | In force (reinstated) | High confidence |
Also on record, not counted in the 6: 9 patents in force now held by others · 30 patents ended. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.